MSLP Muscle Pharm Corporation (CE)

Clinical Study of MusclePharm's Award Winning Pre-Workout Supplement Assault(TM) Published in Nutrition Research Journal

Double-Blind Placebo-Controlled Clinical Trial Confirms Safety and Efficacy of Assault in Recreationally Active Men

DENVER, CO--(Marketwired - Apr 28, 2014) - MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, today announced that Nutrition Research, an international publication for nutrition to advance food and life science research, published the results of a double-blind placebo-controlled clinical study demonstrating safety and efficacy of MusclePharm's pre-workout supplement Assault™.

Results from the trial indicate that the regular use of MusclePharm's pre-workout supplement is safe to consume daily in healthy, recreationally-trained men. In addition, Assault may assist in improvements in lower body strength and ventilatory threshold, the point in progressive exercises at which the first respiratory changes begin to take place. No adverse effects were noted for kidney and liver clinical blood markers, resting heart rate, or blood pressure after the 28-day supplementation period, as tested in the clinical trial protocol.

"Our team of doctors and researchers has done an amazing job creating the only pre-workout supplements on the market that have been clinically proven to safely enhance performance," said Brad Pyatt, Chairman and CEO of MusclePharm. "By taking a science-based approach to product development through our six-stage research protocol, we continue to set the bar in sports nutrition as the leader in innovation and science, giving athletes confidence in the safety and efficacy of our products."

The study was conducted at the United States Sports Academy in collaboration with Georgia Southern University, Statesboro, GA, and the University of Mobile, Mobile, AL.

The paper "Ingesting a pre-workout supplement containing caffeine, creatine, beta-alanine, amino acids, and B-vitamins for 28 days is both safe and efficacious in recreationally active men" is available online ahead of print addition of the print edition at http://www.sciencedirect.com/science/article/pii/S027153171400058X

About MusclePharm's Assault™ Assault is an award winning clinical proven pre-workout nutritional supplement developed at the state-of-the-art MusclePharm® Sports Science Institute, and is among the most researched pre-workout products on the market today. Multiple clinical studies have been published, proving that Assault is a safe and effective supplement that can promote increases in strength, muscular endurance, energy, choice reaction and agility, while decreasing fatigue in healthy men. Assault is one of the only pre-workout products on the market that has certifications from Informed-Choice® as Banned Substance Free on every lot that is produced.

Click here to learn more about MusclePharm's six stage research protocol or visit  http://musclepharmcorp.com/science/6-stage-research-protocol/

About MusclePharm MusclePharm® is a scientifically-driven, performance lifestyle company that currently develops, manufactures, markets and distributes branded nutritional supplements. The company offers a complete range of powders, capsules, tablets and gels. Its portfolio of recognized brands, including MusclePharm® Hybrid and Core Series, Arnold Schwarzenegger Series™ and FitMiss™, are marketed and sold in more than 110 countries and available in over 35,000 retail outlets globally. These clinically-proven and scientific nutritional supplements are developed through a six-stage research process utilizing the expertise of leading nutritional scientists, doctors and universities. MusclePharm is the innovator of the sports nutrition industry. For more information, visit www.musclepharm.com

Follow the company at http://www.facebook.com/MusclePharm and www.Twitter.com/MusclePharm

To sign up to receive MusclePharm news via email, please visit http://ir.musclepharmcorp.com/email-alerts

Forward-Looking Statements  This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof

Contacts: Matt Sheldon/Evan Pondel PondelWilkinson Inc. (310) 279-5980 Investors@musclepharm.com